

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/117068 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) A61P 35/00 (2006.01)
C07K 14/705 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2021/135295

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

03 December 2021 (03.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/133598

03 December 2020 (03.12.2020) CN

(71) Applicants: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US). NANJING LEGEND BIOTECH CO., LTD.
[CN/CN]; No.6 Building of Nanjing Life Science Town,
No. 568 Longmian Avenue, Jiangning District, Nanjing,
Jiangsu 211100 (CN).

(72) Inventors: SCHECTER, Jordan Mark; 920 Rt 202, Rari-
tan, New Jersey 08869 (US). FAN, Xiaohu; 1067 Armitage
Crescent SW, Edmonton, Alberta T6W 0K3 (CA).

(74) Agent: CHINA PATENT AGENT (H.K.) LTD., 22/F.,
Great Eagle Center, 23 Harbour Road, Wanchai, Hong
Kong (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

(57) Abstract: Provided herein is a method of treating a subject who has multiple myeloma. A single infusion of chimeric antigen receptor (CAR) -T cells comprising an anti-BCMA CAR comprising a polypeptide is administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×10^5 to 5.0×10^6 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.

WO 2022/117068 A1